Jelisaveta Džigurski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jelisaveta Džigurski has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Reedik Mägi
6 shared publications- Triin Laisk
Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
6 shared publications Estonian Biobank Research Team
4 shared publicationsKristi Läll
Institute of Genomics, University of Tartu
4 shared publicationsLili Milani
Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
4 shared publicationsTriin Laisk
Institute of Genomics, University of Tartu
4 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (6)
Cohort Profile Update: The Adverse Events Questionnaire of Medications and Vaccines (ADE-Q) in the Estonian Biobank
- 14 October 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (6)
Open AccessCohort Profile Update: The Adverse Events Questionnaire of Medications and Vaccines (ADE-Q) in the Estonian Biobank
- Open Access
Novel loci and multi-omics risk models for rheumatoid arthritis through a million-participant genome-wide association meta-analysis
Rheumatoid arthritis (RA) remains incompletely understood, limiting targeted prevention. In this work, genome-wide association study meta-analyses were performed for RA and seropositive RA, comprising approximately one million participants of European ancestry. Eight and six novel genomic risk loci were defined for RA and seropositive RA, and candidate causal genes were identified, highlighting relevant biological pathways, including established immune pathways and estrogen metabolism. Novel disease-specific polygenic risk scores (PRSs) were constructed, enhancing predictive performance over clinical risk factors (incremental C-statistics of 2.7 and 5.1 for RA and seropositive RA, respectively). In parallel, integrating metabolomic data into high-dimensional models enhanced risk stratification over models based on clinical risk factors and genomics, particularly for seropositive RA, where the hazard ratio of the highest decile increased from 4.869 to 5.697. These findings expand the understanding of genetic factors underlying RA and support the value of including PRSs in risk assessment, while suggesting metabolomic integration may further enhance risk stratification, particularly for seropositive RA.
Open AccessNovel loci and multi-omics risk models for rheumatoid arthritis through a million-participant genome-wide association meta-analysis
Rheumatoid arthritis (RA) remains incompletely understood, limiting targeted prevention. In this work, genome-wide association study meta-analyses were performed for RA and seropositive RA, comprising approximately one million participants of European ancestry. Eight and six novel genomic risk loci were defined for RA and seropositive RA, and candidate causal genes were identified, highlighting relevant biological pathways, including established immune pathways and estrogen metabolism. Novel disease-specific polygenic risk scores (PRSs) were constructed, enhancing predictive performance over clinical risk factors (incremental C-statistics of 2.7 and 5.1 for RA and seropositive RA, respectively). In parallel, integrating metabolomic data into high-dimensional models enhanced risk stratification over models based on clinical risk factors and genomics, particularly for seropositive RA, where the hazard ratio of the highest decile increased from 4.869 to 5.697. These findings expand the understanding of genetic factors underlying RA and support the value of including PRSs in risk assessment, while suggesting metabolomic integration may further enhance risk stratification, particularly for seropositive RA.
- Open Access
Polygenic Risk Links to the Gut Microbiome: The MAGI Catalog
Polygenic risk scores (PRSs) can effectively identify individuals at risk across various health conditions, yet their association with the gut microbiome remains uncharacterized. We systematically analyzed associations between 4,794 PRSs covering 615 traits and diseases and the gut microbiome within the Estonian Microbiome Cohort (N > 2,500). Microbiome diversity was associated with 62 distinct PRSs across 10 traits, indicating that genetic predisposition is linked to significant alterations in the microbiome composition. At the species level, 282 associations were identified across 100 PRSs for 34 traits, with triglyceride measurements, glucose regulation, and chronotype measurement PRSs showing the strongest signals. Mediation analysis suggests that the microbiome is altered by physiological changes linked to genetic risk but can also mediate this risk. These results help define early microbial biomarkers and explain inter-individual variability. The findings are accessible through the interactive Microbiome And Genomic Interaction (MAGI) Catalog to support future research.
Open AccessPolygenic Risk Links to the Gut Microbiome: The MAGI Catalog
Polygenic risk scores (PRSs) can effectively identify individuals at risk across various health conditions, yet their association with the gut microbiome remains uncharacterized. We systematically analyzed associations between 4,794 PRSs covering 615 traits and diseases and the gut microbiome within the Estonian Microbiome Cohort (N > 2,500). Microbiome diversity was associated with 62 distinct PRSs across 10 traits, indicating that genetic predisposition is linked to significant alterations in the microbiome composition. At the species level, 282 associations were identified across 100 PRSs for 34 traits, with triglyceride measurements, glucose regulation, and chronotype measurement PRSs showing the strongest signals. Mediation analysis suggests that the microbiome is altered by physiological changes linked to genetic risk but can also mediate this risk. These results help define early microbial biomarkers and explain inter-individual variability. The findings are accessible through the interactive Microbiome And Genomic Interaction (MAGI) Catalog to support future research.
- Open Access
- 20 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005086
Prescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study
Background: Hormonal contraceptives (HCs) are widely used and have well-documented population-level statistics. Previous studies with short follow-ups have focussed on individual HC use and side effects. However, the same aspects over longer periods, HC formulation switching, and the impact of genetic factors on HC side effects remain understudied due to the limited availability of suitable datasets. We investigated whether the Estonian Biobank (EstBB) is suitable for studying genetic risk for HC side effects. Methods and findings: This is a longitudinal descriptive study combining prescribed HC purchase data collected from 2004 to 2022 with genetic and health data from 73,071 female EstBB HC users aged 15–55 at the time of purchase. HC usage was defined by the Anatomical Therapeutic Chemical (ATC) codes G02B, G03A, and G03HB01. Methods included calculating age-stratified annual user prevalence, inferring usage periods from purchases, assessing formulation switching, identifying the International Classification of Diseases, Tenth Revision (ICD-10)-based side effect-related diagnoses and thromboembolism risk factors, and assessing carrier status for Factor V Leiden (FVL, rs6025) and prothrombin G20210A (PTM, rs1799963) genetic variants as proof-of-concept. Over 19 years, 20 HC formulations with five administration routes (oral pills, transdermal patches, vaginal rings, subdermal implants, intrauterine devices) were used. In the EstBB, combined HCs were the most commonly used among users aged 15–29, while progestin-only HC use increased with age and over time, comparable to the Estonian population. Overall, 64.2% ( n = 46,920) of users switched formulations at least once, with 17.7% ( n = 12,929) being rapid switchers. Side effect-related diagnoses were observed in 23.1% ( n = 2,982) of rapid switchers, with excessive/irregular menstrual bleeding being the most common. Genetic analysis revealed that 5.3% ( n = 3,886) of users carried at least one variant previously associated with increased thrombosis risk (3.5% ( n = 2,556) carried FVL only, 1.8% ( n = 1,276) PTM only, and 0.07% ( n = 54) both). Carriers of thrombosis-associated variants had a significantly higher percentage of thrombosis (6.5%) than non-carriers (4.2%; OR = 1.61, 95% CI [1.40, 1.84], p < 0.001). The study is limited by the use of administrative medication purchase records, which may not reflect actual HC use. Additionally, diagnoses identified near the HC usage period may not represent true side effects. Conclusions: This study provides insights into real-world HC usage with longitudinal, individual-level detail that is not available in population-level statistics. We show that EstBB has a robust dataset for studying the impact of genetic factors on HC side effects and disease risk. The identified HC user profiles offer a framework for genetic analyses of HC rapid switching and discontinuation. Our approach can be replicated in other biobanks to validate findings across populations.
- 20 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005086
Open AccessPrescribed hormonal contraceptive use trends in the Estonian Biobank: A longitudinal observational study
Background: Hormonal contraceptives (HCs) are widely used and have well-documented population-level statistics. Previous studies with short follow-ups have focussed on individual HC use and side effects. However, the same aspects over longer periods, HC formulation switching, and the impact of genetic factors on HC side effects remain understudied due to the limited availability of suitable datasets. We investigated whether the Estonian Biobank (EstBB) is suitable for studying genetic risk for HC side effects. Methods and findings: This is a longitudinal descriptive study combining prescribed HC purchase data collected from 2004 to 2022 with genetic and health data from 73,071 female EstBB HC users aged 15–55 at the time of purchase. HC usage was defined by the Anatomical Therapeutic Chemical (ATC) codes G02B, G03A, and G03HB01. Methods included calculating age-stratified annual user prevalence, inferring usage periods from purchases, assessing formulation switching, identifying the International Classification of Diseases, Tenth Revision (ICD-10)-based side effect-related diagnoses and thromboembolism risk factors, and assessing carrier status for Factor V Leiden (FVL, rs6025) and prothrombin G20210A (PTM, rs1799963) genetic variants as proof-of-concept. Over 19 years, 20 HC formulations with five administration routes (oral pills, transdermal patches, vaginal rings, subdermal implants, intrauterine devices) were used. In the EstBB, combined HCs were the most commonly used among users aged 15–29, while progestin-only HC use increased with age and over time, comparable to the Estonian population. Overall, 64.2% ( n = 46,920) of users switched formulations at least once, with 17.7% ( n = 12,929) being rapid switchers. Side effect-related diagnoses were observed in 23.1% ( n = 2,982) of rapid switchers, with excessive/irregular menstrual bleeding being the most common. Genetic analysis revealed that 5.3% ( n = 3,886) of users carried at least one variant previously associated with increased thrombosis risk (3.5% ( n = 2,556) carried FVL only, 1.8% ( n = 1,276) PTM only, and 0.07% ( n = 54) both). Carriers of thrombosis-associated variants had a significantly higher percentage of thrombosis (6.5%) than non-carriers (4.2%; OR = 1.61, 95% CI [1.40, 1.84], p < 0.001). The study is limited by the use of administrative medication purchase records, which may not reflect actual HC use. Additionally, diagnoses identified near the HC usage period may not represent true side effects. Conclusions: This study provides insights into real-world HC usage with longitudinal, individual-level detail that is not available in population-level statistics. We show that EstBB has a robust dataset for studying the impact of genetic factors on HC side effects and disease risk. The identified HC user profiles offer a framework for genetic analyses of HC rapid switching and discontinuation. Our approach can be replicated in other biobanks to validate findings across populations.
- Open Access
Genetic analysis of female genital tract polyps implicates genome stability, estrogen signalling and shared susceptibility with proliferative gynaecological disorders
Female genital tract (FGT) polyps are common benign growths affecting up to half of all women. However, they carry malignant potential, and their genetic architecture remains poorly defined. We conducted a genome-wide association study (GWAS) meta-analysis across four biobanks (48,400 cases, 477,134 controls), identifying 26 risk loci for FGT polyps, 12 of which were previously unreported. Integrative gene prioritisation highlighted 193 candidate genes, revealing a potential convergent biological mechanism: where germline variation in DNA replication and maintenance (e.g., PRIM1 , TERT and HMGA1 ) compromises genomic stability in the context of hormone-driven proliferation (e.g., ESR1 and GREB1 ). This susceptibility is further modulated by metabolic drivers of estrogen biosynthesis, underscored by specific adiposity-related loci (e.g. RSPO3 and PLCE1 ) and the aromatase gene CYP19A1 . Mendelian randomisation demonstrated bidirectional causal relationships with endometriosis and fibroids, and endometrial cancer. Leveraging the shared genetic architecture of FGT polyps and other gynaecological disorders via multi-trait analysis revealed an additional 26 loci, validating sub-threshold regions encompassing HMGA1 and GREB1. In total, 52 risk loci were identified (36 novel), 39 of which replicated in an independent cohort. These findings reframe polyps not merely as local gynaecological overgrowths but as manifestations of a systemic proliferative syndrome characterised by dysregulated genome stability and estrogen signalling, which may also impact malignant transformation.
Open AccessGenetic analysis of female genital tract polyps implicates genome stability, estrogen signalling and shared susceptibility with proliferative gynaecological disorders
Female genital tract (FGT) polyps are common benign growths affecting up to half of all women. However, they carry malignant potential, and their genetic architecture remains poorly defined. We conducted a genome-wide association study (GWAS) meta-analysis across four biobanks (48,400 cases, 477,134 controls), identifying 26 risk loci for FGT polyps, 12 of which were previously unreported. Integrative gene prioritisation highlighted 193 candidate genes, revealing a potential convergent biological mechanism: where germline variation in DNA replication and maintenance (e.g., PRIM1 , TERT and HMGA1 ) compromises genomic stability in the context of hormone-driven proliferation (e.g., ESR1 and GREB1 ). This susceptibility is further modulated by metabolic drivers of estrogen biosynthesis, underscored by specific adiposity-related loci (e.g. RSPO3 and PLCE1 ) and the aromatase gene CYP19A1 . Mendelian randomisation demonstrated bidirectional causal relationships with endometriosis and fibroids, and endometrial cancer. Leveraging the shared genetic architecture of FGT polyps and other gynaecological disorders via multi-trait analysis revealed an additional 26 loci, validating sub-threshold regions encompassing HMGA1 and GREB1. In total, 52 risk loci were identified (36 novel), 39 of which replicated in an independent cohort. These findings reframe polyps not merely as local gynaecological overgrowths but as manifestations of a systemic proliferative syndrome characterised by dysregulated genome stability and estrogen signalling, which may also impact malignant transformation.
- Open Access
Hormonal contraceptive drug use trends in the Estonian Biobank
Importance: Hormonal contraceptives (HCs) support reproductive goals and alleviate symptoms of gynaecological conditions for millions of women. Despite widespread use, individual long-term HC use trends, medication switching, and impact of genetics on HC side effects remain uncharacterised. Objective: To study HC use trends among Estonian Biobank (EstBB) participants, compare with national statistics, and evaluate suitability of EstBB for studying genetic risk for HC side effects. Design: Longitudinal descriptive analysis of HC refill data collected from 2004–2022 and user profiles, integrating demographic, genetic, and electronic health records data. Setting: Volunteer-based longitudinal cohort representing 20% of Estonian adult population, where participants signed broad informed consent. Participants: Women aged 15–55 in 2004–2022 with complete health and medication history available through linked electronic health records. Exposure: HC use defined as prescription and purchase of drugs of the Anatomical Therapeutic Chemical (ATC) coding system level 3 G02B and G03A, and ATC level 5 G03HB01 during follow-up. Main Outcomes and Measures: Primary measures included age-stratified annual HC users prevalence rates, inferred HC usage period duration, switching frequencies, and user profiles. Secondary measures included HC use during COVID-19 period, and genetic and health-related thromboembolism risk factors. Results: Over 19-year study period, twenty HC formulations with five administration routes (intrauterine device, ring, pill, patch and implant) were used by 73,071 women (mean age at joining EstBB (sd) = 35.6 (10.6)). Comparable to the Estonian population, combined HCs dominated, while progestin-only HC use increased with age and time. Next, 64.3% of users switched formulations at least once, with 17.7% being rapid switchers. Rapid switchers showed side effect-related diagnoses before switching, indicating the dataset's potential for studying genetic risk of side effects. Medical abortion overlapped with inferred usage periods in 3.2% of users, suggesting contraceptive failure. Finally, 5.3% of HC users carried at least one VTE-associated genetic variant, and 1.5% of carriers developed thromboembolism during inferred HC use. Conclusions and Relevance: These HC use trajectories, consistent with population statistics, provide insights into real-world use patterns, offering additional context and support for understanding prescription trends, women's preferences, as well as HC effectiveness and safety. Moreover, EstBB dataset has potential for genetic analyses of HC use and associated side effects.
Open AccessHormonal contraceptive drug use trends in the Estonian Biobank
Importance: Hormonal contraceptives (HCs) support reproductive goals and alleviate symptoms of gynaecological conditions for millions of women. Despite widespread use, individual long-term HC use trends, medication switching, and impact of genetics on HC side effects remain uncharacterised. Objective: To study HC use trends among Estonian Biobank (EstBB) participants, compare with national statistics, and evaluate suitability of EstBB for studying genetic risk for HC side effects. Design: Longitudinal descriptive analysis of HC refill data collected from 2004–2022 and user profiles, integrating demographic, genetic, and electronic health records data. Setting: Volunteer-based longitudinal cohort representing 20% of Estonian adult population, where participants signed broad informed consent. Participants: Women aged 15–55 in 2004–2022 with complete health and medication history available through linked electronic health records. Exposure: HC use defined as prescription and purchase of drugs of the Anatomical Therapeutic Chemical (ATC) coding system level 3 G02B and G03A, and ATC level 5 G03HB01 during follow-up. Main Outcomes and Measures: Primary measures included age-stratified annual HC users prevalence rates, inferred HC usage period duration, switching frequencies, and user profiles. Secondary measures included HC use during COVID-19 period, and genetic and health-related thromboembolism risk factors. Results: Over 19-year study period, twenty HC formulations with five administration routes (intrauterine device, ring, pill, patch and implant) were used by 73,071 women (mean age at joining EstBB (sd) = 35.6 (10.6)). Comparable to the Estonian population, combined HCs dominated, while progestin-only HC use increased with age and time. Next, 64.3% of users switched formulations at least once, with 17.7% being rapid switchers. Rapid switchers showed side effect-related diagnoses before switching, indicating the dataset's potential for studying genetic risk of side effects. Medical abortion overlapped with inferred usage periods in 3.2% of users, suggesting contraceptive failure. Finally, 5.3% of HC users carried at least one VTE-associated genetic variant, and 1.5% of carriers developed thromboembolism during inferred HC use. Conclusions and Relevance: These HC use trajectories, consistent with population statistics, provide insights into real-world use patterns, offering additional context and support for understanding prescription trends, women's preferences, as well as HC effectiveness and safety. Moreover, EstBB dataset has potential for genetic analyses of HC use and associated side effects.
- 25 April 2025
- Published by American Society of Hematology in Blood
Genome-wide Meta-Analysis of Heavy Menstrual Bleeding Reveals 36 Risk Loci
Heavy menstrual bleeding (HMB) is a widespread occurrence among women of reproductive age and inflicts a substantial impact on well-being and healthcare expenses. To better characterize the genetic architecture of HMB, we meta-analyzed GWAS summary statistics from five biobanks, involving up to 84,633 HMB cases and 598,195 controls from several ancestries. Out of 21 signals significantly associated with HMB in a discovery GWAS meta-analysis combining four biobanks, 20 had a concordant direction of effect in the remaining cohort, including 10 significantly replicated. By combining the discovery and replication datasets, 15 additional signals were identified in subsequent meta-analyses. These genetic analyses resulted in 36 signals (33 novel) significantly associated with HMB, and subsequent gene prioritization techniques (e.g., TWAS, PoPS) revealed likely causal genes. Notable discoveries included the strong protective effect of the F5-Leiden variant (rs6025-T, OR=0.75, P=6.8×10-33), variants at the FSHB and LHB/CGB loci, both involved in hormone production regulation, and several signals near genes involved in the Wnt/ß-catenin signaling pathway. We also observed strong and significant genetic correlations with disorders of the female genital tract, including uterine fibroids, endometriosis or ovarian cysts. Overall, we identified 33 novel genetic loci associated with HMB, significantly improving our understanding of the genetic etiology of this condition, which may provide new targets for the development of therapeutic strategies.
- 25 April 2025
- Published by American Society of Hematology in Blood
Genome-wide Meta-Analysis of Heavy Menstrual Bleeding Reveals 36 Risk Loci
Heavy menstrual bleeding (HMB) is a widespread occurrence among women of reproductive age and inflicts a substantial impact on well-being and healthcare expenses. To better characterize the genetic architecture of HMB, we meta-analyzed GWAS summary statistics from five biobanks, involving up to 84,633 HMB cases and 598,195 controls from several ancestries. Out of 21 signals significantly associated with HMB in a discovery GWAS meta-analysis combining four biobanks, 20 had a concordant direction of effect in the remaining cohort, including 10 significantly replicated. By combining the discovery and replication datasets, 15 additional signals were identified in subsequent meta-analyses. These genetic analyses resulted in 36 signals (33 novel) significantly associated with HMB, and subsequent gene prioritization techniques (e.g., TWAS, PoPS) revealed likely causal genes. Notable discoveries included the strong protective effect of the F5-Leiden variant (rs6025-T, OR=0.75, P=6.8×10-33), variants at the FSHB and LHB/CGB loci, both involved in hormone production regulation, and several signals near genes involved in the Wnt/ß-catenin signaling pathway. We also observed strong and significant genetic correlations with disorders of the female genital tract, including uterine fibroids, endometriosis or ovarian cysts. Overall, we identified 33 novel genetic loci associated with HMB, significantly improving our understanding of the genetic etiology of this condition, which may provide new targets for the development of therapeutic strategies.
- Top Cited Papers
- 11 March 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (5) , 1626-1634
Atlas of genetic and phenotypic associations across 42 female reproductive health diagnoses
The genetic background of many female reproductive health diagnoses remains uncharacterized, compromising our understanding of the underlying biology. Here, we map the genetic architecture across 42 female-specific health conditions using data from up to 293,618 women from two large population-based cohorts, the Estonian Biobank and the FinnGen study. Our study illustrates the utility of genetic analyses in understanding women’s health better. As specific examples, we describe genetic risk factors for ovarian cysts that elucidate the genetic determinants of folliculogenesis and, by leveraging population-specific variants, uncover new candidate genes for uterine fibroids. We find that most female reproductive health diagnoses have a heritable component, with varying degrees of polygenicity and discoverability. Finally, we identify pleiotropic loci and genes that function in genital tract development (WNT4, PAX8, WT1, SALL1), hormonal regulation (FSHB, GREB1, BMPR1B, SYNE1/ESR1) and folliculogenesis (CHEK2), underlining their integral roles in female reproductive health.
- 11 March 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (5) , 1626-1634
Top Cited PapersAtlas of genetic and phenotypic associations across 42 female reproductive health diagnoses
The genetic background of many female reproductive health diagnoses remains uncharacterized, compromising our understanding of the underlying biology. Here, we map the genetic architecture across 42 female-specific health conditions using data from up to 293,618 women from two large population-based cohorts, the Estonian Biobank and the FinnGen study. Our study illustrates the utility of genetic analyses in understanding women’s health better. As specific examples, we describe genetic risk factors for ovarian cysts that elucidate the genetic determinants of folliculogenesis and, by leveraging population-specific variants, uncover new candidate genes for uterine fibroids. We find that most female reproductive health diagnoses have a heritable component, with varying degrees of polygenicity and discoverability. Finally, we identify pleiotropic loci and genes that function in genital tract development (WNT4, PAX8, WT1, SALL1), hormonal regulation (FSHB, GREB1, BMPR1B, SYNE1/ESR1) and folliculogenesis (CHEK2), underlining their integral roles in female reproductive health.
- 22 February 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (4) , 750-763
A large-scale genome-wide association study on female genital tract polyps highlights role of DNA repair, cell proliferation, and cell growth
STUDY QUESTION: Can a large-scale genome-wide association study (GWAS) meta-analysis identify genomic risk loci and likely involved genes for female genital tract (FGT) polyps, provide insights into the biological mechanism underlying their development, and inform of potential overlap with other traits, including endometrial cancer? SUMMARY ANSWER: GWAS meta-analysis of FGT polyps highlights potentially shared mechanisms between polyp development and cancerous processes. WHAT IS KNOWN ALREADY: Small-scale candidate gene studies have focused on biological processes such as oestrogen stimulation and inflammation to clarify the biology behind FGT polyps. However, the exact mechanism for the development of polyps is still elusive. At the same time, a genome-wide approach, which has become the gold standard in complex disease genetics, has never been used to uncover the genetics of the FGT polyps. STUDY DESIGN, SIZE, DURATION: We performed a GWAS meta-analysis including a total of 36 984 women with FGT polyps (International Classification of Diseases (ICD-10) diagnosis code N84) and 420 993 female controls (without N84 code) of European ancestry from the FinnGen study (11 092 cases and 94 394 controls), Estonian Biobank (EstBB, 14 008 cases and 112 799 controls), and the Pan-UKBB study (11 884 cases and 213 800 controls). PARTICIPANTS/MATERIALS, SETTING, METHODS: GWAS meta-analysis and functional annotation of GWAS signals were performed to identify genetic risk loci and prioritize genes in associated loci. To explore associations with other traits, we performed a look-up of associated variants across multiple traits and health conditions, genetic correlation analysis, and phenome-wide association study (PheWAS) with ICD-10 diagnosis codes. MAIN RESULTS AND THE ROLE OF CHANCE: Our GWAS meta-analysis revealed 16 significant (P < 5 × 10−8) genomic risk loci. Based on exonic variants in GWAS signals, we prioritized EEFSEC, ODF3, PRIM1, PLCE1, LRRC34/MYNN, EXO1, and CHEK2 which are involved in DNA repair, cell proliferation, and cell growth. Several of the identified genomic loci have previously been linked to endometrial cancer and/or uterine fibroids, highlighting the potentially shared mechanisms underlying tissue overgrowth and cancerous processes. Genetic correlation analysis revealed a positive correlation with body mass index and reproductive traits, that can be classified as symptoms or risk factors of endometrial polyps (EPs), whereas a negative correlation was observed between FGT polyps and both menopause (genetic correlation estimate (rg) = −0.29, SE = 0.08, P = 8.8×10−4) and sex hormone-binding globulin (SHBG) (rg = −0.22, SE = 0.04, P = 2.4×10−8). On the phenotypic level, the strongest associations were observed with endometriosis, uterine fibroids, and excessive, frequent, and irregular menstruation. LARGE SCALE DATA: The complete GWAS summary statistics will be made available after publication through the GWAS Catalog (https://www.ebi.ac.uk/gwas/). LIMITATIONS, REASONS FOR CAUTION: In this study, we focused broadly on FGT polyps and did not differentiate between the polyp subtypes. Considering the prevalence of FGT polyp subtypes, we assumed that most women included in the study had EPs. Further research on the expression profile of FGT polyps could complement the GWAS study to substantiate the functional importance of the identified variants. WIDER IMPLICATIONS OF THE FINDINGS: The study findings have the potential to significantly enhance our understanding of the genetic mechanisms involved, paving the way for future functional follow-up, which in turn could improve the diagnosis, risk assessment, and targeted treatment options, since surgery is the only line of treatment available for diagnosed polyps. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED. Computations were performed in the High-Performance Computing Center of the University of Tartu. The study was also supported by the Estonian Research Council (grant no. PRG1076 and MOBJD1056) and Horizon 2020 innovation grant (ERIN, grant no. EU952516). All the authors declared no conflict of interest.
- 22 February 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (4) , 750-763
A large-scale genome-wide association study on female genital tract polyps highlights role of DNA repair, cell proliferation, and cell growth
STUDY QUESTION: Can a large-scale genome-wide association study (GWAS) meta-analysis identify genomic risk loci and likely involved genes for female genital tract (FGT) polyps, provide insights into the biological mechanism underlying their development, and inform of potential overlap with other traits, including endometrial cancer? SUMMARY ANSWER: GWAS meta-analysis of FGT polyps highlights potentially shared mechanisms between polyp development and cancerous processes. WHAT IS KNOWN ALREADY: Small-scale candidate gene studies have focused on biological processes such as oestrogen stimulation and inflammation to clarify the biology behind FGT polyps. However, the exact mechanism for the development of polyps is still elusive. At the same time, a genome-wide approach, which has become the gold standard in complex disease genetics, has never been used to uncover the genetics of the FGT polyps. STUDY DESIGN, SIZE, DURATION: We performed a GWAS meta-analysis including a total of 36 984 women with FGT polyps (International Classification of Diseases (ICD-10) diagnosis code N84) and 420 993 female controls (without N84 code) of European ancestry from the FinnGen study (11 092 cases and 94 394 controls), Estonian Biobank (EstBB, 14 008 cases and 112 799 controls), and the Pan-UKBB study (11 884 cases and 213 800 controls). PARTICIPANTS/MATERIALS, SETTING, METHODS: GWAS meta-analysis and functional annotation of GWAS signals were performed to identify genetic risk loci and prioritize genes in associated loci. To explore associations with other traits, we performed a look-up of associated variants across multiple traits and health conditions, genetic correlation analysis, and phenome-wide association study (PheWAS) with ICD-10 diagnosis codes. MAIN RESULTS AND THE ROLE OF CHANCE: Our GWAS meta-analysis revealed 16 significant (P < 5 × 10−8) genomic risk loci. Based on exonic variants in GWAS signals, we prioritized EEFSEC, ODF3, PRIM1, PLCE1, LRRC34/MYNN, EXO1, and CHEK2 which are involved in DNA repair, cell proliferation, and cell growth. Several of the identified genomic loci have previously been linked to endometrial cancer and/or uterine fibroids, highlighting the potentially shared mechanisms underlying tissue overgrowth and cancerous processes. Genetic correlation analysis revealed a positive correlation with body mass index and reproductive traits, that can be classified as symptoms or risk factors of endometrial polyps (EPs), whereas a negative correlation was observed between FGT polyps and both menopause (genetic correlation estimate (rg) = −0.29, SE = 0.08, P = 8.8×10−4) and sex hormone-binding globulin (SHBG) (rg = −0.22, SE = 0.04, P = 2.4×10−8). On the phenotypic level, the strongest associations were observed with endometriosis, uterine fibroids, and excessive, frequent, and irregular menstruation. LARGE SCALE DATA: The complete GWAS summary statistics will be made available after publication through the GWAS Catalog (https://www.ebi.ac.uk/gwas/). LIMITATIONS, REASONS FOR CAUTION: In this study, we focused broadly on FGT polyps and did not differentiate between the polyp subtypes. Considering the prevalence of FGT polyp subtypes, we assumed that most women included in the study had EPs. Further research on the expression profile of FGT polyps could complement the GWAS study to substantiate the functional importance of the identified variants. WIDER IMPLICATIONS OF THE FINDINGS: The study findings have the potential to significantly enhance our understanding of the genetic mechanisms involved, paving the way for future functional follow-up, which in turn could improve the diagnosis, risk assessment, and targeted treatment options, since surgery is the only line of treatment available for diagnosed polyps. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED. Computations were performed in the High-Performance Computing Center of the University of Tartu. The study was also supported by the Estonian Research Council (grant no. PRG1076 and MOBJD1056) and Horizon 2020 innovation grant (ERIN, grant no. EU952516). All the authors declared no conflict of interest.
- Top Cited PapersOpen Access
- 28 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Mapping cell-to-tissue graphs across human placenta histology whole slide images using deep learning with HAPPY
Accurate placenta pathology assessment is essential for managing maternal and newborn health, but the placenta’s heterogeneity and temporal variability pose challenges for histology analysis. To address this issue, we developed the ‘Histology Analysis Pipeline.PY’ (HAPPY), a deep learning hierarchical method for quantifying the variability of cells and micro-anatomical tissue structures across placenta histology whole slide images. HAPPY differs from patch-based features or segmentation approaches by following an interpretable biological hierarchy, representing cells and cellular communities within tissues at a single-cell resolution across whole slide images. We present a set of quantitative metrics from healthy term placentas as a baseline for future assessments of placenta health and we show how these metrics deviate in placentas with clinically significant placental infarction. HAPPY’s cell and tissue predictions closely replicate those from independent clinical experts and placental biology literature.
- 28 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Top Cited PapersOpen AccessMapping cell-to-tissue graphs across human placenta histology whole slide images using deep learning with HAPPY
Accurate placenta pathology assessment is essential for managing maternal and newborn health, but the placenta’s heterogeneity and temporal variability pose challenges for histology analysis. To address this issue, we developed the ‘Histology Analysis Pipeline.PY’ (HAPPY), a deep learning hierarchical method for quantifying the variability of cells and micro-anatomical tissue structures across placenta histology whole slide images. HAPPY differs from patch-based features or segmentation approaches by following an interpretable biological hierarchy, representing cells and cellular communities within tissues at a single-cell resolution across whole slide images. We present a set of quantitative metrics from healthy term placentas as a baseline for future assessments of placenta health and we show how these metrics deviate in placentas with clinically significant placental infarction. HAPPY’s cell and tissue predictions closely replicate those from independent clinical experts and placental biology literature.